Adjuvant treatment of melanoma
When is this procedure indicated?
Recent clinical trials have shown the therapeutic efficacy of MAPK pathway inhibitor target therapy and immunotherapy in surgically resected and disease-free patients. Therefore, adjuvant therapy is now considered a standard of care. In particular, in patients with BRAF wild type (i.e. without BRAF mutation) stage IIIA melanoma (with sentinel lymph node metastasis of at least 1 mm), IIIB, IIIC, IIID and IV NED adjuvant therapy with anti PD-1 should be considered as first treatment option. In patients with BRAF V600 mutation and stage IIIA melanoma (with sentinel lymph node metastasis of at least 1 mm), IIIB, IIIC and IIID adjuvant therapy with dabrafenib and trametinib should be considered as first treatment option. The option of clinical protocols using one of the above therapeutic strategies in combination with new drugs remains valid.
How is it performed?
The target therapy is administered through tablets that the patient can easily take at home, while the immunotherapy is administered intravenously.